We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Communication |

Treatment of Retinoblastoma in 2015 Agreement and Disagreement

David H. Abramson, MD1,2; Carol L. Shields, MD3; Francis L. Munier, MD4; Guillermo L. Chantada, MD, PhD5
[+] Author Affiliations
1Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Ophthalmology, Weill-Cornell Medical Center, New York, New York
3Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
4Jules-Gonin Eye Hospital, Faculté de Biologie et Médecine de Lausanne, Lausanne, Switzerland
5Research Institute, Hospital J.P. Garrahan, Buenos Aires, Argentina
JAMA Ophthalmol. 2015;133(11):1341-1347. doi:10.1001/jamaophthalmol.2015.3108.
Text Size: A A A
Published online

The management of intraocular retinoblastoma is rapidly changing, and even recent reviews on the subject are behind existing practices. The 4 authors of this report collectively represent their management strategies with an emphasis on areas of agreement and disagreement. Ophthalmic artery chemosurgery and intravitreous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90% without evidence of compromising patient survival.

Figures in this Article


Place holder to copy figure label and caption
Eyes With Retinoblastoma Before and After Treatment

Eyes are shown before (left) and after treatment (right). All eyes have International Classification of Retinoblastoma group D tumors.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

7 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"

Care at the Close of Life: Evidence and Experience
Chemotherapy and Hormonal Therapy